Literature DB >> 16036053

The risks and benefits of aldosterone antagonists.

Domenic A Sica1.   

Abstract

Spironolactone and eplerenone are mineralocorticoid- blocking agents used for their ability to block a host of epithelial and nonepithelial actions of aldosterone. These compounds are of proven benefit in reducing blood pressure and urine protein excretion, and in conferring cardiovascular gain in diverse circumstances of heart failure. However, as enthusiasm grows for use of mineralocorticoid-blocking agents, the risks inherent to use of such drugs become more pertinent. Whereas the endocrine side effects of spironolactone are in reality little more than a cosmetic disfigurement, the potassium-sparing properties of spironolactone and eplerenone can prove life-threatening if hyperkalemia develops. However, for most patients the risk of developing hyperkalemia should not dissuade the prudent clinician from use of these compounds. Hyperkalemia should be considered as a possibility in any patient receiving these medications and as such is best addressed preemptively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16036053     DOI: 10.1007/s11897-005-0011-5

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  47 in total

1.  Aldosterone is produced from ventricles in patients with essential hypertension.

Authors:  Nobuyasu Yamamoto; Hirofumi Yasue; Yuji Mizuno; Michihiro Yoshimura; Hiromi Fujii; Masafumi Nakayama; Eisaku Harada; Shota Nakamura; Teruhiko Ito; Hisao Ogawa
Journal:  Hypertension       Date:  2002-05       Impact factor: 10.190

2.  Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients.

Authors:  N Ljubicić; M Kujundzić; M Banić; M Vrkljan
Journal:  Scand J Gastroenterol       Date:  1998-04       Impact factor: 2.423

3.  The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis.

Authors:  M J Young; J W Funder
Journal:  Am J Physiol       Date:  1996-11

4.  Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  JAMA       Date:  1973-07-02       Impact factor: 56.272

5.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.

Authors:  K Swedberg; P Eneroth; J Kjekshus; L Wilhelmsen
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

6.  Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Authors:  Ricardo Rocha; Amy E Rudolph; Gregory E Frierdich; Denise A Nachowiak; Beverly K Kekec; Eric A G Blomme; Ellen G McMahon; John A Delyani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

7.  Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data.

Authors:  C S Cook; L M Berry; E Burton
Journal:  Xenobiotica       Date:  2004-03       Impact factor: 1.908

8.  Hydrochlorothiazide and spironolactone in hypertension.

Authors:  G Schrijver; M H Weinberger
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

9.  Efficacy and tolerance of spironolactone in essential hypertension.

Authors:  X Jeunemaitre; G Chatellier; C Kreft-Jais; A Charru; C DeVries; P F Plouin; P Corvol; J Menard
Journal:  Am J Cardiol       Date:  1987-10-01       Impact factor: 2.778

10.  How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?

Authors:  Morten Svensson; Finn Gustafsson; Søren Galatius; Per R Hildebrandt; Dan Atar
Journal:  J Card Fail       Date:  2004-08       Impact factor: 5.712

View more
  4 in total

Review 1.  Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

Review 2.  Diuretic use in renal disease.

Authors:  Domenic A Sica
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

Review 3.  Endocrine causes of secondary hypertension.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-07       Impact factor: 3.738

4.  Differential effects of eplerenone versus amlodipine on muscle metaboreflex function in hypertensive humans.

Authors:  Poghni A Peri-Okonny; Alejandro Velasco; Hamza Lodhi; Zhongyun Wang; Debbie Arbique; Beverley Adams-Huet; Gary Iwamoto; Jere H Mitchell; Masaki Mizuno; Scott Smith; Wanpen Vongpatanasin
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-08-25       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.